News about "Aurobindo Pharma"

Aurobindo Pharma USA Completes Acquisition of Lannett Company

Aurobindo Pharma USA has completed the acquisition of Lannett Company after securing approval from the US Federal Trade Commission. Effective June 29, 2026, Lannett will operate as Lannett Company LLC, with the combined entity aiming to strengthen the supply of essential medicines and enhance value for patients and customers.

Aurobindo Pharma | 30/06/2026 | By News Bureau

US FDA Classifies Aurobindo Pharma's Eugia Unit-III Inspection as Official Action Indicated

Aurobindo Pharma said the US FDA has classified its inspection of Eugia Unit-III in Telangana as Official Action Indicated, while reaffirming its commitment to maintaining global quality manufacturing standards.

Aurobindo Pharma | 16/06/2026 | By News Bureau |  149

CuraTeQ Biologics Secures CDSCO Approval for Bevqolva

CuraTeQ Biologics receives CDSCO marketing authorisation for Bevqolva, strengthening its oncology biosimilars portfolio and expanding access to advanced cancer therapies.

Aurobindo Pharma | 16/05/2026 | By News Bureau |  328

Aurobindo Pharma Extends Timeline for Acquisition of Stake in Swarnaakshu Solar Power

Aurobindo Pharma has announced that the completion of its captive solar power purchase agreement and the acquisition of up to a 26 percent stake in Swarnaakshu Solar Power has been deferred to March 31, 2026, due to pending state government approvals for setting up the solar power plant.

Aurobindo Pharma | 30/12/2025 | By News Bureau |  303

Aurobindo Pharma to Increase Stake in China JV for USD 5.12 Million

Aurobindo Pharma has announced plans to increase its shareholding in its China-based joint venture, Luoxin Aurovitas Pharma (Chengdu), by 20 percent through a cash investment of USD 5.12 million.

Aurobindo Pharma | 26/12/2025 | By Darshana |  257

Aurobindo Pharma's China Facility Running at Loss, Eyes Break-Even by Q4

The company’s CFO, S. Subramanian, indicated that while the plant is operating below margin, it is ramping up production and is on track to contribute positively to the company’s EBITDA in the near future.

Aurobindo Pharma | 24/11/2025 | By Darshana |  141

Aurobindo's Subsidiary CuraTeQ Biologics Completes Phase 3 Clinical Study for Denosumab Biosimilar

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has successfully completed a pivotal clinical study of its denosumab biosimilar, evaluated against Amgen’s Prolia in 446 women with postmenopausal osteoporosis.

Aurobindo Pharma | 19/09/2025 | By Dineshwori |  428

Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions

This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.

Aurobindo Pharma | 18/09/2025 | By Dineshwori |  493

Aurobindo Pharma Expands Business in Malaysia with New Subsidiary

Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V.

Aurobindo Pharma | 18/09/2025 | By Dineshwori |  599

US FDA Completes Inspection at Aurobindo Pharma's Telangana Unit

The inspection of Aurobindo Pharma’s Apitoria Unit-I facility, conducted from 21-29 August, 2025, concluded with five observations.

Aurobindo Pharma | 30/08/2025 | By Dineshwori |  673